Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting®
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
This study was conducted on a total number of 59patients. These were subdivided into 25patients of hepatocellular carcinoma and 34 patients of chronic liver diseases (CLDs) with cirrhosis. All studied 59patients were associated with HCV infection. All patients were examined immunohistochemically to demonstrate the expression of MyeloperoxidaseResultsConcerning the expression of Myeloperoxidase in HCC and cirrhoticpatients; the study revealed that more MPO expression was found in HCC cases when compared with cirrhoticpatients (P –value
AbstractBackground/purposeIn Japan, there is a growing population of patients with chronic hepatitis C virus (HCV) infection who failed a direct-acting antiviral (DAA)-based regimen. In this Phase 3 study, we evaluated sofosbuvir –velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 HCV infection who previously received DAAs.MethodsPatients were randomized 1:1 to receive sofosbuvir –velpatasvir plus ribavirin for 12 or 24 weeks. Randomization was stratified by HCV genotype and presence of cirrhosis. The primary endpoint was sustained virologic response 12-week post-treatment (SVR12).Results...
ANN ARBOR, Mich. (CBS Local) – A disturbing new study declares that a growing number of young Americans are drinking themselves to death. The findings point to a skyrocketing increase in cirrhosis and liver cancer deaths over the last decade. According to the report published in the journal BMJ, deaths due to cirrhosis increased by 65 percent from 2009 to 2016. Deaths from liver cancer doubled (from more than 5,100 to nearly 11,100) during the same time period. Americans between 25-34 were found to be the largest group affected. Cirrhosis is a disease commonly caused by excessive drinking or ...
CONCLUSIONS: This study found a significant association between HBV and integrin α6, which may be responsible for early migration and invasion of HCC. Thus, integrin α6 is a predictive marker for tumor recurrence and invasiveness of HBV-driven HCC. PMID: 30010110 [PubMed - as supplied by publisher]
Conclusion: Given the relationship between the baseline HCC-specific immune surveilling T cell responses and therapy-associated HCC emergence, and the impact of HCV clearance on its strength and magnitude, we recommend a continued HCC screening in cirrhotic HCV patients despite HCV resolution.Liver Cancer
Retrospective studies have found an unexpectedly high incidence of hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV)-associated cirrhosis who received direct-acting antiviral (DAA) agents. We analyzed data from the ANRS CO12 CirVir cohort to compare the incidence of HCC in patients with cirrhosis who received DAA therapy vs patients treated with interferon (IFN).
(CNN) — Death rates from liver cancer increased 43% for American adults from 2000 to 2016, according to a report released Tuesday by the US Centers for Disease Control and Prevention’s National Center for Health Statistics. The increase comes even as mortality for all cancers combined has declined. Liver cancer death rates increased for both men and women 25 and older, as well as white, black and Hispanic people. Only Asians and Pacific Islanders saw a decrease in mortality from liver cancer. The rise in mortality doesn’t mean that liver cancer is deadlier than before, according to Dr. Jiaquan Xu, the aut...
Diabetes is a risk factor of fibrosis progression in chronic hepatitis C (CHC). However, only one longitudinal study exploring whether diabetes is associated with progression from non-cirrhotic liver to cirrhosis in CHC patients has been conducted.
Conclusion The available evidence seems to suggest that combination therapy of (DCV/SOF with RBV) in the treatment of chronic HCV genotype IV naïve difficult to treat patients either cirrhotic or non-cirrhotic is safe and effective. Monitoring for clinical and laboratory hepatic parameters was the basis for these findings. PMID: 30009715 [PubMed - as supplied by publisher]
Journal of Medical Virology, EarlyView.